Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Veoneer in connection with its USD 600 million capital raise
Mandate

Vinge advises Veoneer in connection with its USD 600 million capital raise

May 23, 2019 Capital Markets and Public M&A

Veoneer, Inc. (“Veoneer”) has completed a USD 600 million capital raise, consisting of two concurrent offerings of USD 420 million of shares of common stock and USD 180 million aggregate principal amount of convertible senior notes due 2024.

Veoneer is listed on the New York Stock Exchange (NYSE:VNE) and on Nasdaq Stockholm (SSE: VNE SDB). 

Vinge advises Veoneer in relation to Swedish law. Vinge’s team mainly consist of Göran Nyström, Erik Sjöman, Malte Hedlund, Astrid Isberg, Stephanie Stiernstedt, Viktor Bergsten and Anders Sundin Lundberg. Maria Schultzberg advises on tax issues. 
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024